These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10555946)

  • 1. Successful orchestration of antiparkinsonian pharmacotherapy.
    Scheife RT
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):180S-6S. PubMed ID: 10555946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 3. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
    López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
    Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical inquiry. Which drugs work best for early Parkinson's disease?
    Jain L; Benko R; Safranek S
    J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 8. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's disease: making the diagnosis, selecting drug therapies.
    Scharre DW; Mahler ME
    Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of Sinemet CR4 in patients with Parkinson's disease.
    Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
    N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy of Parkinson's disease].
    Zhou XD
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 20. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.